Gammacan International Inc - Current report filing (8-K)
April 03 2008 - 2:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
March
31, 2008
(Date of Earliest Event Reported)
GAMMACAN INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
0-32835
|
33-0956433
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
39 Jerusalem St.
Kiryat Ono 55423 Israel
(Address of principal executive offices)
(972) (3) 738-2616
(Registrants telephone number, including area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.02
|
Termination
of a Material Definitive Agreement
|
On March 27, 2008, the Registrants subsidiary, GammaCan Ltd. (the
Subsidiary
) sent a notice of
termination, effective March 31, 2008, to Tel HaShomer-Medical Research Infrastructure and Services LTD. (
THM
) terminating the
Research and Licensing Agreement originally entered into on December 13, 2005, as amended during the term (the
THM Agreement
). Under the THM Agreement, the Subsidiary commissioned THM to conduct certain IgG related research activities in return for which THM was entitled to research fees, royalties and warrants.
Termination by the Subsidiary of the THM Agreement was based, in addition to other considerations, on Registrants decision to increase the speed and efficiency at which third party
research is conducted by shifting research activities from a university-driven model to a primarily contract research organization and otherwise commercially-driven model. The Registrant has already transitioned the majority of its research
activities to contract research organizations. In addition, the Registrant is also evaluating whether to establish its own research facility to expedite research activities.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: April 3, 2008
|
By:
|
|
/s/ Patrick
Schnegelsberg
__________
|
|
Name:
|
|
Patrick N.J. Schnegelsberg
|
|
Title:
|
|
Chief Executive
Officer
|
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Aug 2023 to Aug 2024